Clinical Trial

Infectious Complications After Esophagectomy

Study acronym: CIFO
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 17, 2025 (before its estimated July 28, 2026 completion). Its status may not reflect the trial's current state.
Summary
Infectious complications represent the most common postoperative adverse events following esophagectomy for cancer, such as pneumonia (15% of cases). These complications increase immediate risks, lengthen hospital stays, and worsen patient quality of life. The population includes patients admitted to intensive care after esophagectomy for cancer between January 1, 2017, and December 31, 2024. The study focuses on this population due to the increasing incidence of esophageal cancer, the increased use of surgery for these indications, and the importance of postoperative infections in these complex procedures, despite their understudied nature in the current literature. Identifying modifiable risk factors could lead to corrective measures and thus improve the prognosis of postoperative patients. The research focuses primarily on the incidence, types, factors, and prognosis associated with the occurrence of infections after esophagectomy for cancer. It also includes an analysis of the pathogens involved, their resistance profiles, and the antibiotic therapies used in first-line probabilistic treatment.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-03-28; most recent amendment 2025-12-09.
Status change: Not Yet Recruiting → Recruiting 2025-09-15
Trial Details
NCT Number NCT06911658
Lead Sponsor Assistance Publique - Hôpitaux de Paris
Conditions Esophagectomy, Postoperative Complications, Infections, Pneumonia
Enrollment 350 participants
Start Date 2025-08-27
Primary Completion 2026-07-28 (estimated)
Study Completion 2026-07-28 (estimated)
Updated on ClinicalTrials.gov 2025-12-17